Science

Executive Summary

Science Corporation is a clinical-stage medical technology company pioneering advanced brain-computer interface (BCI) systems for serious unmet medical needs. Founded in 2021 and headquartered in San Francisco, the company is initially targeting vision restoration with its lead program, the PRIMA retinal implant. PRIMA is a biohybrid neural interface designed to restore functional vision in patients with retinal degenerative diseases such as age-related macular degeneration (AMD) and retinitis pigmentosa. The device uses a subretinal photovoltaic implant that converts near-infrared light into electrical signals to stimulate retinal neurons, potentially offering higher resolution and less invasive surgery than competing approaches. Science Corporation's vertically integrated model spans device design, manufacturing, and clinical development, positioning it to iterate rapidly and maintain quality control. The company is currently conducting Phase 1 clinical trials to evaluate safety and initial efficacy of PRIMA in patients with severe vision loss. Despite its early stage, Science Corporation has demonstrated promising preclinical and initial clinical results, suggesting the potential for meaningful vision improvement. If successful, PRIMA could become the first BCI-based retinal implant to achieve widespread clinical adoption, addressing a large and growing patient population. However, the company faces significant technical and regulatory hurdles, including long-term biocompatibility, surgical precision, and reimbursement. Given its novel approach and strong IP position, Science Corporation represents a high-risk, high-reward opportunity in the neurotechnology space. Future catalysts include safety and efficacy readouts from ongoing trials, potential FDA breakthrough device designation, and partnership or licensing discussions with major ophthalmology players.

Upcoming Catalysts (preview)

• Q4 2026PRIMA Phase 1 Safety and Efficacy Data Readout75% success
• Q2 2027FDA Breakthrough Device Designation for PRIMA60% success
• 2027Strategic Partnership or Licensing Agreement for PRIMA Commercialization40% success